FDA Officials OK Aflibercept for Diabetic Retinopathy – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
Officials with the US Food and Drug Administration (FDA) have approved aflibercept Injection (Eylea, Regeneron Pharmaceuticals) to treat all stages of diabetic retinopathy (DR), according to a press release from the manufacturer.
Aflibercept Injection is the only vascular endothelial growth factor (VEGF) inhibitor approved with 2 dosing options for DR. The product may be dosed every 8 weeks following 5 initial monthly injections, or every 4 weeks.